Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2017 | Pages:
174 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2017, provides an overview of the B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline landscape. B-Cell Chronic Lymphocytic Leukemia is a type of slow growing leukemia that affects developing B-lymphocytes (also known as B-cells). Symptoms include swollen lymph nodes (glands) in the neck, under the arms or in the groin, pain or discomfort under the ribs on the left side, due to an enlarged spleen, frequent or repeated infections and slow healing, due to a lack of normal white blood cells, excessive sweating at night and unintentional weight loss. Treatment includes chemotherapy and radiation. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide also reviews of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 12, 7, 11 and 3 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 3 and 2 molecules, respectively. B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia (Oncology). - The pipeline guide reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates B-Cell Chronic Lymphocytic Leukemia (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia (Oncology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia (Oncology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia (Oncology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 B-Cell Chronic Lymphocytic Leukemia - Overview 8 B-Cell Chronic Lymphocytic Leukemia - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 13 Products under Development by Companies 14 Products under Development by Universities/Institutes 16 B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 17 Assessment by Target 17 Assessment by Mechanism of Action 20 Assessment by Route of Administration 23 Assessment by Molecule Type 25 B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development 27 AB Science SA 27 Aduro BioTech Inc 27 BioInvent International AB 28 Boehringer Ingelheim GmbH 28 Celgene Corp 29 Cell Source Inc 29 Cellectis SA 30 Dynavax Technologies Corp 30 Elsalys Biotech SAS 31 F. Hoffmann-La Roche Ltd 31 iDD biotech SAS 32 Immunomedics Inc 32 Johnson & Johnson 33 Juno Therapeutics Inc 33 Lymphocyte Activation Technologies SA 34 Mabion SA 34 MedImmune LLC 35 MEI Pharma Inc 35 Millennium Pharmaceuticals Inc 36 Molecular Templates Inc 36 Novartis AG 37 Noxxon Pharma AG 37 Ono Pharmaceutical Co Ltd 38 Portola Pharmaceuticals Inc 38 Regeneron Pharmaceuticals Inc 39 Sunesis Pharmaceuticals Inc 39 TheraMAB LLC 40 Unum Therapeutics Inc 40 B-Cell Chronic Lymphocytic Leukemia - Drug Profiles 41 202-b - Drug Profile 41 2X-121 - Drug Profile 43 AB-8779 - Drug Profile 45 alemtuzumab biosimilar - Drug Profile 46 alisertib - Drug Profile 47 BI-1206 - Drug Profile 53 BI-836826 - Drug Profile 55 BION-1301 - Drug Profile 57 Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile 59 Cellular Immunotherapy for Hematological Malignancies - Drug Profile 60 Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile 61 Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile 63 Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile 65 Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia - Drug Profile 67 Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 68 Cellular Immunotherapy to Target CD19 for B-Cell Malignancies - Drug Profile 69 Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 70 Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 71 Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 72 cerdulatinib - Drug Profile 73 DTRMWXHS-12 - Drug Profile 77 durvalumab - Drug Profile 78 duvortuxizumab - Drug Profile 95 ELB-021 - Drug Profile 97 IDD-001 - Drug Profile 98 IDD-002 - Drug Profile 99 lenalidomide - Drug Profile 100 ME-401 - Drug Profile 117 mRNA ACTR + rituximab - Drug Profile 119 MT-3724 - Drug Profile 121 olaptesed pegol - Drug Profile 124 REGN-1979 - Drug Profile 129 rituximab biosimilar - Drug Profile 130 SD-101 - Drug Profile 132 SNS-062 - Drug Profile 137 TAB-08 - Drug Profile 140 tirabrutinib - Drug Profile 143 tisagenlecleucel-T - Drug Profile 146 tocilizumab - Drug Profile 154 UCART-22 - Drug Profile 164 UCARTCS-1 - Drug Profile 165 B-Cell Chronic Lymphocytic Leukemia - Dormant Projects 166 B-Cell Chronic Lymphocytic Leukemia - Discontinued Products 168 B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 169 Featured News & Press Releases 169 Appendix 171 Methodology 171 Coverage 171 Secondary Research 171 Primary Research 171 Expert Panel Validation 171 Contact Us 171 Disclaimer 172
List of Tables
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Aduro BioTech Inc, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by BioInvent International AB, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Boehringer Ingelheim GmbH, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corp, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cell Source Inc, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Cellectis SA, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corp, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Elsalys Biotech SAS, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics Inc, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Johnson & Johnson, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Lymphocyte Activation Technologies SA, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Mabion SA, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by MedImmune LLC, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by MEI Pharma Inc, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Molecular Templates Inc, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Novartis AG, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Portola Pharmaceuticals Inc, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals Inc, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Sunesis Pharmaceuticals Inc, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Pipeline by Unum Therapeutics Inc, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H2 2017 B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H2 2017 (Contd..1), H2 2017 B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
